Conversations Unplugged
with Boomer Anderson
When Boomer Anderson co-founded Troscriptions in 2020, the goal was not to create another supplement company selling familiar ingredients in familiar formats. Instead, the team started with a simple philosophy: novel ingredients, novel delivery mechanisms. That led them to the buccal troche, a format traditionally seen in hospitals and compounding pharmacies, and eventually to products built around areas such as stress, sleep, energy, and cognitive performance. In this conversation with STEMREGEN Founder and Chief Science Officer Christian Drapeau, Boomer explains why innovation often means going all the way back to sourcing, formulation, and sometimes even growing or synthesizing an ingredient yourself.
Boomer Anderson
Behind Troscriptions is a broader philosophy that began with Health Optimization Medicine and Practice, the nonprofit organization Boomer says actually came first. Rather than focusing exclusively on disease, its clinicians are trained to examine what Boomer calls the “root causes of health.” That includes looking at the metabolome to better understand the nutrients, minerals, cofactors, and hormones that may influence cellular function. For Boomer, the goal is to give people more individualized information before they invest in the growing number of technologies and interventions available in the longevity world.
Troscriptions grew out of a practical gap in that model. Boomer explains that foundational changes involving nutrition, hormones, and behavior can take months, while someone struggling with sleep, stress, or another immediate concern may want support now. His team therefore develops products intended to serve as shorter-term tools while practitioners work with clients on longer-term changes. Boomer even says his ideal outcome is that people eventually no longer need the products, an unusual philosophy for a company whose business depends on selling them.
That emphasis on doing something genuinely different is where Boomer and Christian find common ground. Boomer describes a development process that begins with a specific problem, examines potential mechanisms, and then searches for the most promising ingredients, even when sourcing requires unconventional solutions. Christian shares a similar experience developing new plant-based compounds, including one his team is currently investigating for its effects on autophagy in laboratory testing. Boomer closes with a lesson he carried from his former career in investment banking: if you are going to create something, make it meaningfully different. For both men, innovation begins where simply making another version of what already exists stops being interesting.
